AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05557097 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intrapartum sonography
Description: Intrapartum ultrasound performed as an adjunct to clinical examination to assess fetal occiput position prior to performing vacuum delivery
Study NCT05851092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2189 Tablets
Description: HRS-2189 Tablets
Study NCT06508775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-CART19.1
Description: Assessment of long-term safety and efficacy of MB-CART19.1 treatment.
Study NCT06508775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-CART20.1
Description: Assessment of long-term safety and efficacy of MB-CART20.1 treatment.
Study NCT06508775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-CART2019.1
Description: Assessment of long-term safety and efficacy of MB-CART2019.1 treatment.
Study NCT05418166 — intervention group
Intervention type: DRUG
Intervention: Evolocumab
Description: evolocumab 140mg subcutaneous injection after regular take Ticagrelor and Aspirin for 5 days.
Study NCT03058653 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Small fluid boluses of 50 ml
Description: Participants will receive small 50ml boluses of fluid up to 250ml in total. The remainder will be given as infusion pump method at a rate of 1000ml/hour which will complete in 15 minutes. In total, the 500ml will be given over 25 minutes.
Study NCT03058653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LIDCORapid Monitor
Description: Addition of the LIDCORapid Monitor to measure stroke volume
Study NCT05325073 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Erythropoietin
Description: Erythropoietin
Study NCT04636060 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eisen
Description: Treatment with low-dose iron in the form of tablets containing 6mg of iron. Treatment consists of twice-daily oral administration of iron-tablets for 8 weeks in total.
Study NCT05073952 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Connective tissue graft
Description: Implants will be placed with a flap and a connective tissue graft.
Study NCT05073952 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flapless
Description: Implants will be placed with a flapless approach
Study NCT05494645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: Liposomal bupivicaine
Study NCT05494645 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Nerve Block
Description: Peripheral nerve block without Exparel
Study NCT04820686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VBR
Description: VBR is an HBV core protein inhibitor. Participants will receive VBR 300 mg tablets orally once daily (QD).
Study NCT04820686 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: VBR
Description: VBR is an HBV core protein inhibitor. Participants will receive VBR 300 mg tablets orally once daily (QD).
Study NCT04820686 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AB-729
Description: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants will receive a 60-mg subcutaneous injection of AB-729 once every 8 weeks.
Study NCT04820686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-729
Description: AB-729 is a small interfering ribonucleic acid (siRNA) inhibitor of HBV. Participants will receive a 60-mg subcutaneous injection of AB-729 once every 8 weeks.
Study NCT04820686 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: SOC NrtI
Description: Participants will receive their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert.
Study NCT04820686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC NrtI
Description: Participants will receive their SOC NrtI (ETV, TDF or TAF) tablet orally as per approved package insert.
Study NCT06187779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower segment measurment
Description: Lower segment measurement will be taken prior to induction with a balloon catheter (ATAD).
Study NCT05278533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioPlete™ Advanced Formula
Description: 2 capsules, twice a day for a total of 4 capsules daily, preferably with a meal
Study NCT05278533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules, twice a day for a total of 4 capsules daily, preferably with a meal
Study NCT03418272 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Culture/PCR Analysis
Description: Microbes to be selectively cultured and PCR analysis to be conducted. Bacteria obtained in samples will be dispersed in non-selective Mueller Hinton Broth (Sigma-Aldrich), divided into two separate cultures and grown overnight at 37°C in aerobic condition and in 5% CO2 to assure survival of both aerobic and facultative anaerobic species.~* Staphylococcus aureus (MSSA, MRSA)~* Pseudomonas aeruginosa~* Haemophilus influenza~* Streptococcus pneumonia~* Streptococcus Pyogenes Group B streptococci,~* Klebsiella pneumonia~* Moraxella catarrhalis
Study NCT05771506 — intervention group
Intervention type: OTHER
Intervention: Balance Assessment
Description: Balance assessment will be done with the Biodex Balance System® (Biodex Medical Systems, Shirley, New York, United States). Postural stability test overall score, stability limits test overall score, and sensory integration test of balance composite score will be recorded.
Study NCT05771506 — intervention group
Intervention type: OTHER
Intervention: Pulmonary function test
Description: Pulmonary function test will be performed with a spirometer (COSMED Pony FX (COSMED; Italy) in accordance with ATS/ERS criteria. Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), FEV1/FVC, peak expiratory volume measured at 25% and 75% of forced expiratory time (FEF 25-75%), and peak expiratory volume (PEF) parameters will be measured. The results will be recorded both as a percentage of measured values and expected values.
Study NCT05771506 — intervention group
Intervention type: OTHER
Intervention: Respiratory muscle strength test
Description: Respiratory muscle strength will be measured in accordance with ATS/ERS criteria using an electronic, mobile, (MicroRPM, Micro Medical; UK) intraoral pressure measuring device. Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP) values will be recorded. Three measurements will be repeated for each maneuver and the highest value recorded as cmH2O.
Study NCT05771506 — intervention group
Intervention type: OTHER
Intervention: Peripheral muscle strength test
Description: Peripheral muscle strength will be assessed by measuring M. Quadriceps muscle strength with a digital handheld dynamometer (MicroFET® Hoggan Scientific; USA). The test will be done in three measurements for the dominant side lower extremity. The average of the obtained values will be recorded in kilograms.
Study NCT05771506 — intervention group
Intervention type: OTHER
Intervention: 6-minute walk test
Description: Functional capacity will be assessed with the 6-minute walk test (6MWT). 6MWT will be performed in accordance with the criteria of the American Thoracic Society. The 6MWT distance will be recorded in meters.
Study NCT05771506 — intervention group
Intervention type: OTHER
Intervention: Cognitive assessment
Description: Cognitive function will be assessed with the Montreal Cognitive Assessment (MoCA) test. The MoCA test is a questionnaire developed to evaluate different cognitive functions and mild cognitive impairment. The maximum score that an individual can obtain from the test is 30, and a score of 21 or above is considered as mild cognitive impairment. Test; will be administered by a certified physiotherapist who has received training on practice and scoring directives
Study NCT05702398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: 1,000 μg retinyl palmitate twice a day for 6 months
Study NCT05702398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: 500 mg NAM twice a day for 6 months
Study NCT05939635 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral ultrasound guided external oblique intercostal block (EOIB)
Description: Bilateral ultrasound-guided EOIB (total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA Multimodal analgesia : Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, and iv paracetamol 1 gr and 0.05 mg/kg, ideal body weight (IBW), iv morphine will be administered. End of the surgery, hyoscine-N-butyl bromide will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5 mg/ml morphine (the bolus dose is 20 μg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). In cases where rescue analgesia is required (NRS score ≥4), 50 mg of meperidine is administered to patients.~Patients are routinely administered ondansetron 8 mg IV 20 minutes before extubation for postoperative nausea and vomiting prophylaxis.
Study NCT05939635 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral ultrasound guided Modified thoracoabdominal nerves block through perichondrial approach(M-TAPA) block
Description: Bilateral ultrasound guided Modified thoracoabdominal nerves block through perichondrial approach(M-TAPA) block (total of 60 ml, %0.25 bupivacaine) will be performed + IV morphine PCA Multimodal analgesia : Patients are administered iv tenoxicam 20mg and tramadol 100 mg after induction of general anesthesia, and iv paracetamol 1 gr and 0.05 mg/kg, ideal body weight (IBW), iv morphine will be administered. End of the surgery, hyoscine-N-butyl bromide will be administered. Postoperative analgesia: iv paracetamol 1gr every 8 hours and IV PCA of 0,5 mg/ml morphine (the bolus dose is 20 μg/kg, the lock-in time of 6-10 minutes, the 4-hour limit is adjusted to be 80% of the calculated total amount). In cases where rescue analgesia is required (NRS score ≥4), 50 mg of meperidine is administered to patients.~Patients are routinely administered ondansetron 8 mg IV 20 minutes before extubation for postoperative nausea and vomiting prophylaxis.
Study NCT05939635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV morphine patient-controlled analgesia (PCA)
Description: Morphine will be administered via PCA device for the first 24 hours after surgery
Study NCT05672823 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter Aortic Valve Implantation (TAVI)
Description: Comparing different accessory access sites for TAVI: the temporary pacemaker access site and the diagnostic access site.
Study NCT05672823 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Implantation (TAVI)
Description: Comparing different accessory access sites for TAVI: the temporary pacemaker access site and the diagnostic access site.
Study NCT03415061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Insulin, Human 100 UNT/ML
Description: 40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.
Study NCT03415061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline Flush, 0.9% Injectable Solution
Description: Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery
Study NCT05226546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma (PRP)
Description: PRP injections were performed in each olfactory cleft by nasal endoscopy and under local anesthesia, a sniffing stick test was performed before the injection and one month after
Study NCT05226546 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: olfactory training
Description: The investigators compare the result of the PRP group to a control group how underwent simple olfactive training for one month.~The control group matched for age, gender and olfactory score at baseline. The patients had a sniffing stick test at the beginning and also after one month of olfactory training.
Study NCT05702398 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Other: Placebo
Description: Identical placebo pills twice a day
Study NCT05023850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TLIPB
Description: Patients will receive TLIPB with an injection of 40 ml of bupivacaine 0.25% (2 injections of 20 ml on each side) between multifidus and longissimus muscles.
Study NCT05023850 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESPB
Description: Patients will receive ESPB with an injection of 40 ml of bupivacaine 0.25% (2 injections of 20 ml on each side) between erector spinae muscle and transverse process of a vertebra.
Study NCT06293716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVL237 tablets
Description: CVL237 tablets, tablets, specification: 0.1g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.
Study NCT06293716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CVL237 placebo tablets
Description: CVL237 tablets, tablets, specification: 0g, Storage condition: not more than 30 ℃ storage.Validity: 72 months tentatively.
Study NCT05600361 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: hyperpolarized 13C-labeled pyruvate from dynamic nuclear polarization (DNP) magnetic resonance spectroscopy
Description: In stage 1, we expected to enroll 8 first-time diagnosed lymphoma patients referred from clinicians for 13C-pyruvate DNP MRS. In stage 2, another 8 patients with proven relapse will be referred from clinicians for 13C-pyruvate DNP MRS. We will collect related clinical information, patient follow up information, including treatment outcome, and imaging parameters from MRI and PET/CT.
Study NCT04217707 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pre- and Post-Surgical Transgender Therapeutic Support Group
Description: Participants will be patients drawn from already-existing therapeutic support groups for transgender patients who are hoping to undergo or have undergone gender-affirming surgeries. Participants will be assured that there will be no changes to their care or decisions about their surgeries if they elect not to participate in the research portion of the groups, but would still like to attend groups as a non-research participant. Prior to their first group session, participants will be arrive early to go over consent again and allow participants to sign the consent form and fill out baseline measures of the outcomes of interest. Following this, research participants will participate in the groups as usual, and after each of their first 8 attended sessions, will be asked to fill out outcomes of interest again. Length of time for them to attend 8 sessions will be capped at 6 months, and participants will be asked to fill out measures again at six months following their enrollment.
Study NCT04710498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab administered intravenous (IV) infusion at a fixed dose of 1200 mg
Study NCT06084533 — intervention group
Intervention type: DRUG
Intervention: [11C]-CS1P1
Description: Participants will receive a single intravenous bolus injection of 10.0 - 20.0 milliCurie (mCi) of the investigational radiotracer \[11C\]-CS1P1. Participants will then undergo a \[11C\]-CS1P1 PET scan.
Study NCT06485726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproic Acid 500 MG
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The treatment safety was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Study NCT05106595 — intervention group
Intervention type: DEVICE
Intervention: Bimanual Arm Trainer
Description: tabletop/desktop device that couples bilateral simultaneous upper extremity movement with virtual reality games or activities via computer monitor
Study NCT06485726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The treatment safety was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Study NCT05595551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The intervention Aan Tafel in 1, 2, 3 euro
Description: The participants in this group are clients of Colruyt who are subscribed to the program Aan Tafel in 1 2 3 euro. They will receive two-weekly recipe booklets with 6 balanced and child-friendly recipes in each booklet. They are guaranteed a fixed price for each recipe, that will be given at the checkout counter, based on their loyalty card.
Study NCT06362447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin Injectable Solution
Description: Gentamicin (10 mg/kg) will be administrated once weekly for 3 months
Study NCT04836572 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 3M 1529 Adhesive Tape
Description: 5-12 hour adhesive wear
Study NCT06265246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Habitual Diet + Milk
Description: 1.5 servings of milk \[providing approx. 500 mg Ca/day\] per day (either 1% fat milk, or 2% fat milk)
Study NCT06265246 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Habitual Diet + Yogurt
Description: 2 servings of yogurt \[providing approx. 500 mg Ca/day\] per day (either 1% fat plain yogurt, 2% fat plain yogurt, 1% fat flavoured yogurt, 2% fat flavoured yogurt)
Study NCT04889807 — intervention group
Intervention type: OTHER
Intervention: measure of EtCO2 variation
Description: measure of EtCO2 (end tidal carbon dioxide) variation after an 15 seconds end-expiratory occlusion test
Study NCT05419999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix 1x1 tDCS mini CT
Description: During stimulation, a current flows between the electrodes passing through the brain to complete the circuit. tDCS is hypothesized to modulate intrinsic neuronal activity by enhancing neuronal resting potential, or altering the likelihood that a neuron will (or will not) depolarize.
Study NCT05419999 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Soterix 1x1 tDCS Mini CT
Description: Sham setting is used on the Soterix transcranial electrical stimulator
Study NCT05419999 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Written Exposure Therapy (WET)
Description: An exposure-based, behavioral psychotherapy for PTSD.
Study NCT05419999 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy (WET)
Description: An exposure-based, behavioral psychotherapy for PTSD.
Study NCT05649397 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical manipulation
Description: provide a high velocity, low-amplitude manipulation to each subject's cervical spine.
Study NCT05649397 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: 15 mins moist hot pack Neck Isometric exercise hold for 5-8 seconds and repeat 10 times Cervical range of motion 10 repetitions of movement in rotation within pain free range
Study NCT05862246 — intervention group
Intervention type: OTHER
Intervention: Clinical examination
Description: No intervention, only clinical examination
Study NCT05134324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active rTMS
Description: Participants recevied 1 Hz low frequency repetetive TMS during 20 minutes and a total of 1200 stimuli for 15 sessions. Motor threshold was defined as the minimum stimulus intensity eliciting 5 responses of about 50 µV out of 10 consecutive trials (50% successful MEPS) in the relaxed contralateral abductor pollicis brevis (APB).The patient received robotic therapy for upper extremity just after each active TMS sessions.
Study NCT05134324 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: Participants recevied sham TMS during 20 minutes and a total of 1200 sham stimuli for 15 sessions with sham coil employed was identical in shape and size to the real stimulation coil and produced no magnetic field. The patient received robotic therapy for upper extremity just after each sham TMS sessions.
Study NCT05134324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active tDCS
Description: Participants recevied 2 mA anodal transcranial direct current stimulation 20 minutes for 15 sessions.The electrodes will be placed anodal to the C3/C4 (International 10/20 Electroencephalogram System) area, corresponding to the location of the affected hemisphere primary motor cortex (M1), and cathodal to the contralateral supraorbital region. The patient received robotic therapy for upper extremity just after each active tDCS sessions.
Study NCT05134324 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Participants recevied sham stimulation were applied current was ramped up either over 10 seconds, with an equal amount of time for tapering off. The patient received robotic therapy for upper extremity just after each sham tDCS sessions
Study NCT05176860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CBCT Imaging
Description: Two research CBCT images will be acquired per subject.
Study NCT05542693 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RNA MCTI CIMATEC HDT 5µg
Description: Adults previously immunized will be randomized to receive a single booster vaccine: experimental (MCTI-CIMATEC-HDT RNA)